Irinotecan is a chemotherapy agent used primarily in the treatment of colorectal cancer and other solid tumors. It was developed in the 1990s and later approved for medical use following clinical trials demonstrating its effectiveness as a topoisomerase I inhibitor. Its history is marked by its significant role in improving survival outcomes in advanced colorectal cancer, but also by the recognition of dose-limiting toxicities such as severe diarrhea and neutropenia, which led to careful dosing strategies and supportive care protocols during treatment. Irinotecan, a semisynthetic derivative of camptothecin, was incorporated into combination chemotherapy regimens such as folfiri and became an important component of modern oncology practice. Its development included extensive clinical trials and post-marketing surveillance to optimize efficacy while managing its significant adverse effect profile.
BRAND NAMES
Camptosar – original and widely recognized brand (notably in the US)
Campto – commonly used brand in Europe and other regions
Onivyde – liposomal formulation used in pancreatic and metastatic cancers, often in combination regimens.
MECHANISM OF ACTION
Irinotecan is a prodrug that is converted in the body (mainly in the liver) to its active metabolite SN-38. SN-38 exerts its anticancer effect by inhibiting the enzyme topoisomerase I, which is essential for DNA replication and transcription.
PHARMACOKINETICS
Absorption
Irinotecan is administered intravenously, so it has 100% systemic bioavailability with no absorption phase as seen with oral drugs. After IV infusion, it rapidly enters the systemic circulation and is widely distributed to tissues.
Distribution
The active metabolite SN-38 also shows significant tissue binding, contributing to both therapeutic effects and toxicity. This extensive distribution reflects its ability to penetrate tissues rather than remain confined to plasma.
Metabolism
Irinotecan is extensively metabolized in the body, primarily in the liver. It is converted by carboxylesterase enzymes into its active metabolite SN-38, which is significantly more potent in inhibiting topoisomerase I and is mainly responsible for both therapeutic effects and toxicity.
Elimination
Irinotecan is eliminated through both biliary and renal routes, primarily after hepatic metabolism. The active metabolite SN-38 and its inactive glucuronide form (SN-38G) are excreted mainly in the bile into the feces, with a smaller portion eliminated via urine.
PHARMACODYNAMICS
Irinotecan exerts its pharmacological effects through its active metabolite SN-38, which inhibits the enzyme topoisomerase I. This enzyme is responsible for relieving torsional stress in DNA by inducing reversible single-strand breaks during replication and transcription.
ADMINISTRATION
Irinotecan is administered intravenously (IV) only under the supervision of an oncology specialist in a hospital or cancer treatment center. It is typically given as an IV infusion over 30–90 minutes, depending on the treatment protocol (e.g., FOLFIRI regimen or monotherapy schedules). The dosing schedule is usually once every 1–3 weeks, adjusted based on body surface area, patient tolerance, and blood count recovery.
DOSAGE AND STRENGTH
Irinotecan is supplied as an intravenous formulation in multiple strengths, commonly including 40 mg/2 mL (20 mg/mL), 100 mg/5 mL, and 300 mg/15 mL vials, depending on the manufacturer and clinical setting. The dosing is individualized and typically based on body surface area (mg/m²) rather than fixed doses.
DRUG INTERACTIONS
Irinotecan has several clinically important drug interactions that primarily involve hepatic metabolism and can significantly affect both its efficacy and toxicity. Drugs that induce CYP3A4 enzymes, such as rifampin, carbamazepine, phenytoin, and St.
FOOD INTERACTIONS
Irinotecan has no major direct food–drug interactions, as it is administered intravenously and is not affected by gastrointestinal absorption of nutrients. However, diet can indirectly influence its tolerability, especially its gastrointestinal side effects.
CONTRAINDICATIONS
Irinotecan is contraindicated in patients with a known hypersensitivity to irinotecan or any of its components. It should not be used in individuals with severe bone marrow suppression, including marked neutropenia or thrombocytopenia, as it can further worsen hematologic toxicity.
SIDE EFFECTS
Severe diarrhea (early cholinergic or late-onset secretory diarrhea)
Nausea and vomiting
Myelosuppression (especially neutropenia, leukopenia, thrombocytopenia)
Abdominal cramps and pain
Alopecia (hair loss)
Fatigue and weakness
Dehydration (secondary to diarrhea and vomiting)
Cholinergic symptoms (early onset): sweating, salivation, lacrimation, abdominal cramping.
OVER DOSE
Overdose of Irinotecan can lead to severe and potentially life-threatening toxicities, primarily due to excessive formation and accumulation of its active metabolite SN-38. The most critical effects include profound myelosuppression, particularly severe neutropenia, which greatly increases the risk of serious infections and sepsis.
TOXICITY
Toxicity of Irinotecan is primarily dose-limiting and is closely related to its active metabolite SN-38, which can accumulate depending on individual metabolic capacity, especially UGT1A1 activity. The most clinically significant toxicities include severe neutropenia, which increases the risk of life-threatening infections, and dose-dependent diarrhea, which may present as early cholinergic diarrhea or delayed secretory diarrhea and can lead to dehydration and electrolyte imbalance.
